29 results on '"Nwana, N."'
Search Results
2. Phase 2 GEOMETRY Mono-1 Study: Capmatinib in Patients with METex14-mutated Advanced Non-Small Cell Lung Cancer who Received Prior Immunotherapy
- Author
-
Heist, R. S., Vansteenkiste, J., Smit, E., Groen, H., Garon, E., Hida, T., Nishio, M., Kokowski, K., Grohe, C., Reguart, N., Mansfield, A., Robeva, A., Ghebremariam, S., Waldron-Lynch, M., Akimov, M., Nwana, N., Giovannini, M., and Wolf, J.
- Published
- 2021
3. Accurate Detection of METex14 Mutations in Non-Small Cell Lung Cancer (NSCLC) with Comprehensive Genomic Sequencing: Results from the GEOMETRY Mono-1 Study
- Author
-
Heist, R. S., Garon, E. B., Tan, D. S. W., Groen, H. J. M., Seto, T., Smit, E. F., Nwana, N., Fairchild, L., Balbin, A., Yan, M., Wang, I., Giovannini, M., Sankaran, B., and Wolf, J.
- Published
- 2020
4. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
- Author
-
Schuler, M. (Martin), Berardi, R. (R.), Lim, W.-T. (W. T.), de Jonge, M. (M.), Bauer, T.M. (T. M.), Azaro, A. (A.), Gottfried, M. (M.), Han, J.-Y. (J. Y.), Lee, D.H. (D. H.), Wollner, M. (M.), Hong, D.S. (D. S.), Vogel, A. (A.), Delmonte, A. (A.), Akimov, M. (M.), Ghebremariam, S. (S.), Cui, X. (X.), Nwana, N. (N.), Giovannini, M. (M.), Kim, T.M. (T. M.), Schuler, M. (Martin), Berardi, R. (R.), Lim, W.-T. (W. T.), de Jonge, M. (M.), Bauer, T.M. (T. M.), Azaro, A. (A.), Gottfried, M. (M.), Han, J.-Y. (J. Y.), Lee, D.H. (D. H.), Wollner, M. (M.), Hong, D.S. (D. S.), Vogel, A. (A.), Delmonte, A. (A.), Akimov, M. (M.), Ghebremariam, S. (S.), Cui, X. (X.), Nwana, N. (N.), Giovannini, M. (M.), and Kim, T.M. (T. M.)
- Abstract
Background: Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs in 3%–4% of non-small-cell lung cancer (NSCLC) and is associated with unfavorable prognosis. While MET is a validated drug target in lung cancer, the best biomarker strategy for the enrichment of a susceptible patient population still remains to be defined. Towards this end we analyze here primary data from a phase I dose expansion study of the MET inhibitor capmatinib in patients with advanced MET-dysregulated NSCLC. Patients and methods: Eligible patients [≥18 years; Eastern Cooperative Oncology Group (ECOG) performance status ≤2] with MET-dysregulated advanced NSCLC, defined as either (i) MET status by immunohistochemistry (MET IHC) 2+ or 3+ or H-score ≥150, or MET/centromere ratio ≥2.0 or gene copy number (GCN) ≥5, or (ii) epidermal growth factor receptor wild-type (EGFRwt) and centrally assessed MET IHC 3+, received capmatinib at the recommended dose of 400 mg (tablets) or 600 mg (capsules) b.i.d. The primary objective was to determine safety and tolerability; the key secondary objective was to explore antitumor activity. The exploratory end point was the correlation of clinical activity with different biomarker formats. Results: Of 55 patients with advanced MET-dysregulated NSCLC, 40/55 (73%) had received two or more prior systemic therapies. All patients discontinued treatment, primarily due to disease progression (69.1%). The median treatment dura
- Published
- 2020
- Full Text
- View/download PDF
5. Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study
- Author
-
Vansteenkiste, J. F., Smit, E. F., Groen, H. J. M., Garon, E. B., Heist, R. S., Hida, T., Nishio, M., Kokowski, K., Grohe, C., Reguart, N., Mansfield, A. S., Robeva, A., Ghebremariam, S., Waldron-Lynch, M., Akimov, M., Nwana, N., Giovannini, M., Wolf, J., Vansteenkiste, J. F., Smit, E. F., Groen, H. J. M., Garon, E. B., Heist, R. S., Hida, T., Nishio, M., Kokowski, K., Grohe, C., Reguart, N., Mansfield, A. S., Robeva, A., Ghebremariam, S., Waldron-Lynch, M., Akimov, M., Nwana, N., Giovannini, M., and Wolf, J.
- Published
- 2020
6. Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study
- Author
-
Wolf, J., Groen, H. J. M., Akerley, W., Souquet, P. -J., Laack, E., Han, J. -Y., Smit, E. F., Mansfield, A. S., Garon, E. B., Tan, D. S. W., Heist, R. S., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M., Orlov, S., Wolf, J., Groen, H. J. M., Akerley, W., Souquet, P. -J., Laack, E., Han, J. -Y., Smit, E. F., Mansfield, A. S., Garon, E. B., Tan, D. S. W., Heist, R. S., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M., and Orlov, S.
- Published
- 2020
7. Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study
- Author
-
Wolf, J., Overbeck, T., Han, J. -Y., Hochmair, M., De Marinis, F., Ohashi, K., Smit, E. F., Power, D., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M., Heist, R. S., Wolf, J., Overbeck, T., Han, J. -Y., Hochmair, M., De Marinis, F., Ohashi, K., Smit, E. F., Power, D., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M., and Heist, R. S.
- Published
- 2020
8. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
- Author
-
Schuler, M, Berardi, R, Lim, WT, de Jonge, Maja, Bauer, TM, Azaro, A, Gottfried, M, Han, JY, Lee, D H, Wollner, M, Hong, DS, Vogel, A, Delmonte, A, Akimov, M, Ghebremariam, S, Cui, X, Nwana, N, Giovannini, M, Kim, TM, Schuler, M, Berardi, R, Lim, WT, de Jonge, Maja, Bauer, TM, Azaro, A, Gottfried, M, Han, JY, Lee, D H, Wollner, M, Hong, DS, Vogel, A, Delmonte, A, Akimov, M, Ghebremariam, S, Cui, X, Nwana, N, Giovannini, M, and Kim, TM
- Published
- 2020
9. MO01.21 Phase 2 GEOMETRY Mono-1 Study: Capmatinib in Patients with METex14-mutated Advanced Non-Small Cell Lung Cancer who Received Prior Immunotherapy
- Author
-
Heist, R.S., primary, Vansteenkiste, J., additional, Smit, E., additional, Groen, H., additional, Garon, E., additional, Hida, T., additional, Nishio, M., additional, Kokowski, K., additional, Grohe, C., additional, Reguart, N., additional, Mansfield, A., additional, Robeva, A., additional, Ghebremariam, S., additional, Waldron-Lynch, M., additional, Akimov, M., additional, Nwana, N., additional, Giovannini, M., additional, and Wolf, J., additional
- Published
- 2021
- Full Text
- View/download PDF
10. 1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study
- Author
-
Vansteenkiste, J.F., primary, Smit, E.F., additional, Groen, H.J.M., additional, Garon, E.B., additional, Heist, R.S., additional, Hida, T., additional, Nishio, M., additional, Kokowski, K., additional, Grohe, C., additional, Reguart, N., additional, Mansfield, A.S., additional, Robeva, A., additional, Ghebremariam, S., additional, Waldron-Lynch, M., additional, Akimov, M., additional, Nwana, N., additional, Giovannini, M., additional, and Wolf, J., additional
- Published
- 2020
- Full Text
- View/download PDF
11. B11 Accurate Detection of METex14 Mutations in Non-Small Cell Lung Cancer (NSCLC) with Comprehensive Genomic Sequencing: Results from the GEOMETRY Mono-1 Study
- Author
-
Heist, R.S., primary, Garon, E.B., additional, Tan, D.S.W., additional, Groen, H.J.M., additional, Seto, T., additional, Smit, E.F., additional, Nwana, N., additional, Fairchild, L., additional, Balbin, A., additional, Yan, M., additional, Wang, I., additional, Giovannini, M., additional, Sankaran, B., additional, and Wolf, J., additional
- Published
- 2020
- Full Text
- View/download PDF
12. B11 Accurate Detection of METex14Mutations in Non-Small Cell Lung Cancer (NSCLC) with Comprehensive Genomic Sequencing: Results from the GEOMETRY Mono-1 Study
- Author
-
Heist, R.S., Garon, E.B., Tan, D.S.W., Groen, H.J.M., Seto, T., Smit, E.F., Nwana, N., Fairchild, L., Balbin, A., Yan, M., Wang, I., Giovannini, M., Sankaran, B., and Wolf, J.
- Published
- 2020
- Full Text
- View/download PDF
13. Green Streets, Healthy Hearts: Exploring the Roles of Urban Nature and Walkability in Cardiovascular Health.
- Author
-
Nwana N, Javed Z, Jones SL, Lee C, Maddock JE, Al-Kindi S, and Nasir K
- Subjects
- Humans, Protective Factors, Residence Characteristics, Risk Reduction Behavior, Health Status, Risk Assessment, Heart Disease Risk Factors, Cardiovascular Diseases prevention & control, Cardiovascular Diseases epidemiology, Cardiovascular Diseases physiopathology, Cardiovascular Diseases diagnosis, Walking, Urban Health, Built Environment, City Planning, Environment Design
- Abstract
With the growing evidence that connects urban environments with public health outcomes, the role of urban planning has become increasingly critical in addressing public health challenges. Cardiovascular diseases (CVDs) are the leading cause of mortality in urban areas and worldwide and are impacted by characteristics of the built environment, such as walkability and nature exposure. In this literature view, we explore the influence of the physical built environment, specifically green spaces and walkability, on cardiovascular health. Results from prior studies show a clear reduction in cardiovascular disease-related risk factors, morbidity, and mortality in neighborhoods that integrate green spaces and/or walkability. Cumulative evidence suggests that urban environments that integrate green spaces (such as parks) and walkability (eg, safe sidewalks) can significantly improve cardiovascular health. Urban planning policies and strategies that prioritize the integration of green infrastructure and walkable designs can contribute to improving cardiovascular health in urban residents while also enhancing the overall well-being and quality of life., Competing Interests: The authors have no competing interests to declare., (Copyright: © 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
14. Burden of Atherosclerotic Disease Risk Factors in Patients With and Without Rheumatologic Disease: A Retrospective Cohort Study.
- Author
-
DiGregorio H, Avenatti E, Gullapelli R, Williams K, El Hajj E, Foster C, Das S, Shahid I, Shah A, Nicolas J, Bose B, Hagan K, Lahan S, Nwana N, Butt S, Javed Z, Karam LR, Monga K, Guevara M, Weber B, Patel K, Al-Kindi SG, and Nasir K
- Subjects
- Humans, Retrospective Studies, Female, Male, Middle Aged, Risk Factors, Aged, Atherosclerosis epidemiology, Rheumatic Diseases epidemiology, Rheumatic Diseases complications
- Abstract
Competing Interests: Declaration of competing interest The authors have no competing interests to declare.
- Published
- 2024
- Full Text
- View/download PDF
15. Building a Novel Artificial Intelligence-Driven Echocardiographic Data Pipeline: Findings From a Large Learning Health System.
- Author
-
Bose B, Butt SA, Arshad HB, Nicolas CC, Gullapelli R, Nwana N, Javed Z, Shahid I, Pournazari P, Patel K, Chamsi Pasha MA, Little SH, Faza NS, Jones S, Cainzos MA, Al-Kindi S, Saad JM, Zoghbi W, Nagueh SF, and Nasir K
- Subjects
- Humans, Learning Health System, Artificial Intelligence, Echocardiography methods
- Abstract
Competing Interests: Conflicts of interest None.
- Published
- 2024
- Full Text
- View/download PDF
16. Neighborhood Walkability Is Associated With Lower Burden of Cardiovascular Risk Factors Among Cancer Patients.
- Author
-
Nwana N, Makram OM, Nicolas JC, Pan A, Gullapelli R, Parekh T, Javed Z, Titus A, Al-Kindi S, Guan J, Sun K, Jones SL, Maddock JE, Chang J, and Nasir K
- Abstract
Background: Modifiable cardiovascular risk factors constitute a significant cause of cardiovascular disease and mortality among patients with cancer. Recent studies suggest a potential link between neighborhood walkability and favorable cardiovascular risk factor profiles in the general population., Objectives: This study aimed to investigate whether neighborhood walkability is correlated with favorable cardiovascular risk factor profiles among patients with a history of cancer., Methods: We conducted a cross-sectional study using data from the Houston Methodist Learning Health System Outpatient Registry (2016-2022) comprising 1,171,768 adults aged 18 years and older. Neighborhood walkability was determined using the 2019 Walk Score and divided into 4 categories. Patients with a history of cancer were identified through International Classification of Diseases-10th Revision-Clinical Modification codes (C00-C96). We examined the prevalence and association between modifiable cardiovascular risk factors (hypertension, diabetes, smoking, dyslipidemia, and obesity) and neighborhood walkability categories in cancer patients., Results: The study included 121,109 patients with a history of cancer; 56.7% were female patients, and 68.8% were non-Hispanic Whites, with a mean age of 67.3 years. The prevalence of modifiable cardiovascular risk factors was lower among participants residing in the most walkable neighborhoods compared with those in the least walkable neighborhoods (76.7% and 86.0%, respectively). Patients with a history of cancer living in very walkable neighborhoods were 16% less likely to have any risk factor compared with car-dependent-all errands neighborhoods (adjusted OR: 0.84, 95% CI: 0.78-0.92). Sensitivity analyses considering the timing of events yielded similar results., Conclusions: Our findings demonstrate an association between neighborhood walkability and the burden of modifiable cardiovascular risk factors among patients with a medical history of cancer. Investments in walkable neighborhoods may present a viable opportunity for mitigating the growing burden of modifiable cardiovascular risk factors among patients with a history of cancer., Competing Interests: The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
17. Houston Methodist cardiovascular learning health system (CVD-LHS) registry: Methods for development and implementation of an automated electronic medical record-based registry using an informatics framework approach.
- Author
-
Nasir K, Gullapelli R, Nicolas JC, Bose B, Nwana N, Butt SA, Shahid I, Cainzos-Achirica M, Patel K, Bhimaraj A, Javed Z, Andrieni J, Al-Kindi S, Jones SL, and Zoghbi WA
- Abstract
Objectives: To investigate the potential value and feasibility of creating a listing system-wide registry of patients with at-risk and established Atherosclerotic Cardiovascular Disease (ASCVD) within a large healthcare system using automated data extraction methods to systematically identify burden, determinants, and the spectrum of at-risk patients to inform population health management. Additionally, the Houston Methodist Cardiovascular Disease Learning Health System (HM CVD-LHS) registry intends to create high-quality data-driven analytical insights to assess, track, and promote cardiovascular research and care., Methods: We conducted a retrospective multi-center, cohort analysis of adult patients who were seen in the outpatient settings of a large healthcare system between June 2016 - December 2022 to create an EMR-based registry. A common framework was developed to automatically extract clinical data from the EMR and then integrate it with the social determinants of health information retrieved from external sources. Microsoft's SQL Server Management Studio was used for creating multiple Extract-Transform-Load scripts and stored procedures for collecting, cleaning, storing, monitoring, reviewing, auto-updating, validating, and reporting the data based on the registry goals., Results: A real-time, programmatically deidentified, auto-updated EMR-based HM CVD-LHS registry was developed with ∼450 variables stored in multiple tables each containing information related to patient's demographics, encounters, diagnoses, vitals, labs, medication use, and comorbidities. Out of 1,171,768 adult individuals in the registry, 113,022 (9.6%) ASCVD patients were identified between June 2016 and December 2022 (mean age was 69.2 ± 12.2 years, with 55% Men and 15% Black individuals). Further, multi-level groupings of patients with laboratory test results and medication use have been analyzed for evaluating the outcomes of interest., Conclusions: HM CVD-LHS registry database was developed successfully providing the listing registry of patients with established ASCVD and those at risk. This approach empowers knowledge inference and provides support for efforts to move away from manual patient chart abstraction by suggesting that a common registry framework with a concurrent design of data collection tools and reporting rapidly extracting useful structured clinical data from EMRs for creating patient or specialty population registries., Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Khurram Nasir reports a relationship with Nova Nordisk, Novartis, Esperion, Amgen, National Institutes of Health, and the Jerold B. Katz Academy of Translational Research that includes: consulting or advisory, funding grants, and speaking and lecture fees. All other authors report no relevant disclosures., (© 2024 Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
18. Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
- Author
-
Wolf J, Souquet PJ, Goto K, Cortot A, Baik C, Heist R, Kim TM, Han JY, Neal JW, Mansfield AS, Gilloteau I, Nwana N, Waldron-Lynch M, Davis KL, Giovannini M, and Awad MM
- Subjects
- Humans, Retrospective Studies, Mutation genetics, Proto-Oncogene Proteins c-met genetics, Proto-Oncogene Proteins genetics, Protein Kinase Inhibitors therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Abstract
Background: We evaluated the disease and patient characteristics, treatment, and MET testing patterns, predictive biomarkers and survival outcomes in patients with MET-dysregulated metastatic non-small-cell lung cancer (NSCLC) in a real-world setting., Patients and Methods: This was a multinational, retrospective, noninterventional chart review study. Data from medical records of patients with advanced/metastatic EGFR wild-type, MET-dysregulated NSCLC (December 2017-September 2018) were abstracted into electronic data collection forms., Results: Overall, 211 patient charts were included in this analysis; 157 patients had MET exon 14 skipping mutations (METex14; with or without concomitant MET amplification) and 54 had MET amplification only. All patients were tested for METex14, whereas MET amplification was evaluated in 168 patients. No overlap was reported between MET dysregulation and ALK, ROS1 or RET rearrangements, or HER2 exon 20 insertions. Overall, 56 of 211 patients (26.5%) received MET inhibitor (METi) therapy in any treatment-line setting (31.2% in the METex14 cohort; 13% in the MET-amplified only cohort). In the METex14 cohort, median OS in patients receiving METi was 25.4 months versus 10.7 months in patients who did not (HR [95% CI]: 0.532 [0.340-0.832]; P = .0055). In the MET-amplified only cohort, median OS was 20.6 months in patients treated with METi compared with 7.6 months in those without METi (HR [95% CI]: 0.388 [0.152-0.991]; P = .0479)., Conclusions: MET alterations in NSCLC typically occur in the absence of other oncogenic driver mutations and are associated with poor survival outcomes. Notably, METi therapies are associated with improved survival outcomes in patients with MET-dysregulated NSCLC., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
19. Cumulative social disadvantage and health-related quality of life: national health interview survey 2013-2017.
- Author
-
Hagan K, Javed Z, Cainzos-Achirica M, Hyder AA, Mossialos E, Yahya T, Acquah I, Valero-Elizondo J, Pan A, Nwana N, Taha M, and Nasir K
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Hispanic or Latino, Odds Ratio, Surveys and Questionnaires, Quality of Life, Social Determinants of Health, Socioeconomic Disparities in Health
- Abstract
Background: Evidence for the association between social determinants of health (SDoH) and health-related quality of life (HRQoL) is largely based on single SDoH measures, with limited evaluation of cumulative social disadvantage. We examined the association between cumulative social disadvantage and the Health and Activity Limitation Index (HALex)., Methods: Using adult data from the National Health Interview Survey (2013-2017), we created a cumulative disadvantage index by aggregating 47 deprivations across 6 SDoH domains. Respondents were ranked using cumulative SDoH index quartiles (SDoH-Q1 to Q4), with higher quartile groups being more disadvantaged. We used two-part models for continuous HALex scores and logistic regression for poor HALex (< 20th percentile score) to examine HALex differences associated with cumulative disadvantage. Lower HALex scores implied poorer HRQoL performance., Results: The study sample included 156,182 respondents, representing 232.8 million adults in the United States (mean age 46 years; 51.7% women). The mean HALex score was 0.85 and 17.7% had poor HALex. Higher SDoH quartile groups had poorer HALex performance (lower scores and increased prevalence of poor HALex). A unit increase in SDoH index was associated with - 0.010 (95% CI [-0.011, -0.010]) difference in HALex score and 20% higher odds of poor HALex (odds ratio, OR = 1.20; 95% CI [1.19, 1.21]). Relative to SDoH-Q1, SDoH-Q4 was associated with HALex score difference of -0.086 (95% CI [-0.089, -0.083]) and OR = 5.32 (95% CI [4.97, 5.70]) for poor HALex. Despite a higher burden of cumulative social disadvantage, Hispanics had a weaker SDoH-HALex association than their non-Hispanic White counterparts., Conclusions: Cumulative social disadvantage was associated with poorer HALex performance in an incremental fashion. Innovations to incorporate SDoH-screening tools into clinical decision systems must continue in order to accurately identify socially vulnerable groups in need of both clinical risk mitigation and social support. To maximize health returns, policies can be tailored through community partnerships to address systemic barriers that exist within distinct sociodemographic groups, as well as demographic differences in health perception and healthcare experience., (© 2023. BioMed Central Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
20. Body Mass Index and All-Cause and Cardiovascular Mortality in United States Adults With and Without Atherosclerotic Cardiovascular Disease: Findings from the National Health Interview Survey.
- Author
-
Taha MB, Javed Z, Nwana N, Acquah I, Satish P, Sharma G, Sabouret P, Cainzos-Achirica M, and Nasir K
- Subjects
- Aged, Young Adult, Humans, Adolescent, Adult, Body Mass Index, Overweight epidemiology, Ethnicity, Obesity epidemiology, Cardiovascular Diseases epidemiology
- Abstract
In a nationally representative population-based study of US adults, the authors sought to examine the association between body mass index (BMI) and all-cause and cardiovascular disease (CVD) mortality in a nationally representative sample of adults with and without atherosclerotic cardiovascular disease (ASCVD), and further stratified by age, sex, and race/ethnicity. The study used data from 2006 to 2015 National Health Interview Survey and categorized participants into the following BMI categories: normal weight (20-24.9), overweight (25-29.9), obesity class 1 (30-34.9), obesity class 2 (35-39.9), and obesity class 3 (≥40 kg/m
2 ). Multivariable Cox proportional hazards models were used to assess the risk of all-cause and CVD mortality across successively increasing BMI categories overall, and by sociodemographic subgroups. A total of 210,923 individuals were included in the final analysis. In the population without ASCVD, the risk of all-cause and CVD mortality was lower in overweight and higher in obesity classes 2 and 3, compared with normal weight, with the highest risk observed in the young adult (age 18-39) population. Elderly adults (65 and above) and populations with ASCVD exhibited a BMI-mortality paradox. In addition, Hispanic individuals did not show a relationship between BMI and mortality compared with non-Hispanic White and Black adults. In conclusion, being overweight was associated with decreased risk, whereas obesity class 3 was consistently associated with increased risk of all-cause and CVD mortality in adults without ASCVD, particularly young adults. BMI-mortality paradox was noted in ASCVD, elderly, and non-Hispanic adults.- Published
- 2023
- Full Text
- View/download PDF
21. Favorable Neighborhood Walkability is Associated With Lower Burden of Cardiovascular Risk Factors Among Patients Within an Integrated Health System: The Houston Methodist Learning Health System Outpatient Registry.
- Author
-
Makram OM, Nwana N, Nicolas JC, Gullapelli R, Pan A, Bose B, Parekh T, Al-Kindi S, Yahya T, Hagan K, Javed Z, Patel K, Sharma G, Jones SL, Cainzos-Achirica M, Maddock JE, and Nasir K
- Subjects
- Adult, Humans, Middle Aged, Walking, Outpatients, Cross-Sectional Studies, Protestantism, Risk Factors, Heart Disease Risk Factors, Registries, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control, Learning Health System, Delivery of Health Care, Integrated
- Abstract
This is the first study to investigate the relationship between neighborhood walkability and cardiovascular (CV) risk factors in the United States using a large population-based database. Cross-sectional study using data from 1.1 million patients over the age of 18 in the Houston Methodist Learning Health System Outpatient Registry (2016-2022). Using the 2019 WalkScore, patients were assigned to one of the 4 neighborhood walkability categories. The burden of CV risk factors (hypertension, diabetes, obesity, dyslipidemia, and smoking) was defined as poor, average, or optimal (>3, 1-2, 0 risk factors, respectively). We included 887,654 patients, of which 86% resided in the two least walkable neighborhoods. The prevalence of CV risk factors was significantly lower among participants in the most walkable neighborhoods irrespective of ASCVD status. After adjusting for age, sex, race/ethnicity, and socioeconomic factors, we found that adults living in the most walkable neighborhoods were more likely to have optimal CV risk profile than those in the least walkable ones (RRR 2.77, 95% CI 2.64-2.91). We observed an inverse association between neighborhood walkability and the burden of CV risk factors. These findings support multilevel health system stakeholder engagements and investments in walkable neighborhoods as a viable tool for mitigating the growing burden of modifiable CV risk factors., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
22. Social Determinants of Cardiovascular Risk, Subclinical Cardiovascular Disease, and Cardiovascular Events.
- Author
-
Acquah I, Hagan K, Javed Z, Taha MB, Valero-Elizondo J, Nwana N, Yahya T, Sharma G, Gulati M, Hammoud A, Shapiro MD, Blankstein R, Blaha MJ, Cainzos-Achirica M, and Nasir K
- Subjects
- Humans, Risk Factors, Social Determinants of Health, Inflammation, Heart Disease Risk Factors, Cardiovascular Diseases diagnosis, Cardiovascular Diseases epidemiology, Atherosclerosis
- Abstract
Background Although there is research on the impact of social determinants of health (SDOHs) on cardiovascular health, most existing evidence is based on individual SDOH components. We evaluated the impact of cumulative SDOH burden on cardiovascular risk factors, subclinical atherosclerosis, and incident cardiovascular disease events. Methods and Results We included 6479 participants from the MESA (Multi-Ethnic Study of Atherosclerosis). A weighted aggregate SDOH score representing the cumulative number of unfavorable SDOHs, identified from 14 components across 5 domains (economic stability, neighborhood and physical environment, community and social context, education, and health care system access) was calculated and divided into quartiles (quartile 4 being the least favorable). The impact of cumulative SDOH burden on cardiovascular risk factors (hypertension, diabetes, dyslipidemia, smoking, and obesity), systemic inflammation, subclinical atherosclerosis, and incident cardiovascular disease was evaluated. Increasing social disadvantage was associated with increased odds of all cardiovascular risk factors except dyslipidemia. Smoking was the risk factor most strongly associated with worse SDOH (odds ratio [OR], 2.67 for quartile 4 versus quartile 1 [95% CI, 2.13-3.34]). Participants within SDOH quartile 4 had 33% higher odds of increased high-sensitivity C-reactive protein (OR, 1.33 [95% CI, 1.11-1.60]) and 31% higher risk of all cardiovascular disease (hazard ratio, 1.31 [95% CI, 1.03-1.67]), yet no greater burden of subclinical atherosclerosis (OR, 1.01 [95% CI, 0.79-1.29]), when compared with those in quartile 1. Conclusions Increasing social disadvantage was associated with more prevalent cardiovascular risk factors, inflammation, and incident cardiovascular disease. These findings call for better identification of SDOHs in clinical practice and stronger measures to mitigate the higher SDOH burden among the socially disadvantaged to improve cardiovascular outcomes.
- Published
- 2023
- Full Text
- View/download PDF
23. Neighborhood deprivation and morbid obesity: Insights from the Houston Methodist Cardiovascular Disease Health System Learning Registry.
- Author
-
Nwana N, Taha MB, Javed Z, Gullapelli R, Nicolas JC, Jones SL, Acquah I, Khan S, Satish P, Mahajan S, Cainzos-Achirica M, and Nasir K
- Abstract
This study examined the relationship between a validated measure of socioeconomic deprivation, such as the Area Deprivation Index (ADI), and morbid obesity. We used cross-sectional data on adult patients (≥18 years) in the Houston Methodist Cardiovascular Disease Health System Learning Registry (located in Houston, Texas, USA) between June 2016 and July 2021. Each patient was grouped by quintiles of ADI, with higher quintiles signaling greater deprivation. BMI was calculated using measured height and weight with morbid obesity defined as ≥ 40 kg/m
2 . Multivariable logistic regression models were used to examine the association between ADI and morbid obesity adjusting for demographic (age, sex, and race/ethnicity) factors. Out of the 751,174 adults with an ADI ranking included in the analysis, 6.9 % had morbid obesity (n = 51,609). Patients in the highest ADI quintile had a higher age-adjusted prevalence (10.9 % vs 3.3 %), and about 4-fold odds (aOR, 3.8; 95 % CI = 3.6, 3.9) of morbid obesity compared to the lowest ADI quintile. We tested for and found interaction effects between ADI and each demographic factor, with stronger ADI-morbid obesity association observed for patients that were female, Hispanic, non-Hispanic White and 40-65 years old. The highest ADI quintile also had a high prevalence (44 %) of any obesity (aOR, 2.2; 95 % CI = 2.1, 2.2). In geospatial mapping, areas with higher ADI were more likely to have higher proportion of patients with morbid obesity. Census-based measures, like the ADI, may be informative for area-level obesity reduction strategies as it can help identify neighborhoods at high odds of having patients with morbid obesity., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2022 Published by Elsevier Inc.)- Published
- 2022
- Full Text
- View/download PDF
24. Hospitalization and survival of solid organ transplant recipients with coronavirus disease 2019: A propensity matched cohort study.
- Author
-
Swan JT, Rizk E, Jones SL, Nwana N, Nicolas JC, Tran AT, Xu J, Nisar T, Menser T, Yi SG, Moore LW, Huang HJ, Ghobrial RM, Gaber AO, and Knight RJ
- Subjects
- Humans, Cohort Studies, Retrospective Studies, Hospitalization, Transplant Recipients, COVID-19, Organ Transplantation
- Abstract
Background: Solid organ transplant (SOT) recipients are predicted to have worse COVID-19 outcomes due to their compromised immunity. However, this association remains uncertain because published studies have had small sample sizes and variability in chronic comorbidity adjustment., Methods: In this retrospective cohort study conducted at a multihospital health system, we compared COVID-19 outcomes and survival up to 60 days following hospital admission in SOT recipients taking baseline immunosuppressants versus hospitalized control patients., Results: The study included 4,562 patients who were hospitalized with COVID-19 (108 SOT recipients and 4,454 controls) from 03/2020 to 08/2020. Mortality at 60 days was higher for SOT recipients (17% SOT vs 10% control; unadjusted odds ratio (OR) = 1.74, 95% confidence interval (CI) 1.04-2.91, P = 0.04). We then conducted a 1:5 propensity matched cohort analysis (100 SOT recipients; 500 controls) using age, sex, race, body mass index, hypertension, diabetes, chronic kidney disease, liver disease, admission month, and area deprivation index. Within 28 days of admission, SOT recipients had fewer hospital-free days (median; 17 SOT vs 21 control; OR = 0.64, 95%CI 0.46-0.90, P = 0.01) but had similar ICU-free days (OR = 1.20, 95%CI 0.72-2.00, P = 0.49) and ventilator-free days (OR = 0.91, 95%CI 0.53-1.57, P = 0.75). There was no statistically significant difference in 28-day mortality (9% SOT vs 12% control; OR = 0.76, 95%CI 0.36-1.57, P = 0.46) or 60-day mortality (16% SOT vs 14% control; OR = 1.15, 95%CI 0.64-2.08, P = 0.64)., Conclusions: Hospitalized SOT recipients appear to need additional days of hospital care but can achieve short-term mortality outcomes from COVID-19 that are similar to non-SOT recipients in a propensity matched cohort study., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2022 Swan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2022
- Full Text
- View/download PDF
25. Does hospital location matter? Association of neighborhood socioeconomic disadvantage with hospital quality in US metropolitan settings.
- Author
-
Nwana N, Chan W, Langabeer J, Kash B, and Krause TM
- Subjects
- United States, Humans, Vulnerable Populations, Socioeconomic Factors, Residence Characteristics, Hospitals
- Abstract
An aspect of a hospital's location, such as its degree of socioeconomic disadvantage, could potentially affect quality ratings of the hospital; yet, few studies have granularly explored this relationship in United States (US) metropolitan areas characterized by a wide breadth of socioeconomic disparities across neighborhoods. An understanding of the effect of neighborhood socioeconomic disadvantage on hospital quality of care is informative for targeting resources in poor neighborhoods. We assessed the association of neighborhood socioeconomic disadvantage with hospital quality of care across several areas of quality (including mortality, readmission, safety, patient experience, effectiveness of care, summary and overall star rating) in US metropolitan areas. Hospitals in the most disadvantaged neighborhoods, compared to hospitals in the least disadvantaged neighborhoods, had worse mortality scores, readmission scores, safety of care scores, patient experience of care scores, effectiveness of care scores, summary scores and overall star rating. Timeliness of care and efficient use of imaging scores were not strongly associated with neighborhood socioeconomic disadvantage; although, future studies are needed to validate this finding. Policymakers could target innovative strategies for improving neighborhood socioeconomic conditions in more disadvantaged areas, as this may improve hospital quality., Competing Interests: Declaration of competing interest No conflicts of interest relevant to the content of this manuscript were reported by the authors., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
26. Effectiveness of Bariatric Surgery in Increasing Kidney Transplant Eligibility in Patients with Kidney Failure Requiring Dialysis.
- Author
-
Soliman BG, Tariq N, Law YY, Yi S, Nwana N, Bosetti R, Kash B, Moore LW, Gaber AO, and Sherman V
- Subjects
- Female, Gastrectomy, Humans, Middle Aged, Postoperative Complications, Renal Dialysis, Retrospective Studies, Treatment Outcome, Bariatric Surgery, Gastric Bypass, Kidney Transplantation, Laparoscopy, Obesity, Morbid surgery, Renal Insufficiency
- Abstract
Purpose: Severe obesity can increase risk of complications after kidney transplantation. There is a paucity of literature on bariatric surgery outcomes in renal transplant candidates. The objective of this study was to analyze outcomes of bariatric surgery as a weight reduction strategy for patients with kidney failure to enhance eligibility for kidney transplantation., Materials and Methods: We performed a retrospective analysis of the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program database at a single institution for patients with chronic kidney disease receiving hemodialysis therapy (CKD G5D) undergoing bariatric surgery between 2011 and 2018., Results: Of 2363 patients who underwent bariatric surgery, 38 (1.6%) had CKD G5D; median age (range) was 49 years (33; 69), 52.6% were female, and mean BMI was 44.2 kg/m
2 . Twenty-four patients underwent laparoscopic Roux-en-Y gastric bypass (LRYGB), and 14 patients underwent laparoscopic sleeve gastrectomy. Seventeen patients (46%, n=37) had a BMI≤35 at 6 months, while 25 patients (75.8%, n=33) achieved a BMI≤35 at 12 months. Of these, 18 patients (47%) were listed for kidney transplant, and 8 patients (21%) received kidney transplant. There was no statistically significant difference between sleeve and LRYGB procedures in patients who reached BMI of 35 at 12 months (P=0.58). Median length of stay was 2.3 days. Thirty-day readmission rate was 2 patients (5.3%), and 2 patients (5.3%) required reoperation (one for bleeding, one for acute recurrent hiatal hernia). No mortality occurred., Conclusion: Laparoscopic bariatric surgery offers effective weight loss for CKD G5D patients to achieve transplant eligibility with acceptable outcomes., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)- Published
- 2021
- Full Text
- View/download PDF
27. Diabetes Education Desert: Regional Disparity Between Diabetes Prevalence and Diabetes Self-Management Education Programs in Texas.
- Author
-
Baek J, Cheon O, Lee S, and Nwana N
- Subjects
- Humans, Prevalence, Self Care, Texas epidemiology, United States, Diabetes Mellitus epidemiology, Self-Management
- Abstract
Diabetes is a major chronic disease that was the seventh leading cause of death in the United States in 2017. Although diabetes self-management education (DSME) programs have been implemented to promote patients' self-management skills, the disease continues to grow and some regions have a heavier burden of diabetes diagnoses than others. Focusing on the unbalanced diabetes prevalence across counties, this study aims to identify regional distribution of diabetes education programs in Texas counties, and explore whether diabetes prevalence is worse in certain counties that are geographically isolated from DSME programs. Data from the Centers for Disease Control and Prevention, American Diabetes Association, and American Association of Diabetes Educators were analyzed using ESRI ArcGIS software. When the authors geocoded 167 DSME programs in Texas, it was found that 47 programs (28.7%) were concentrated in 1 single county, and only 49 counties (19.3%) of the total counties (n = 254) had at least 1 DSME program. It also was revealed that the 25 counties (10%) with the highest diabetes prevalence had only 4 DSME programs (2.4%), indicating that there are still marginalized areas with no access to diabetes education programs. Considering the distance from each county's center to the nearest DSME program and diabetes prevalence, 3 counties were identified as diabetes education deserts. When designing, implementing, and evaluating strategies to reduce the burden of diabetes, policy makers and health care providers should account for the existing regional disparity in diabetes education and its impact on diabetes prevalence.
- Published
- 2021
- Full Text
- View/download PDF
28. Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness.
- Author
-
Nwana N, Marks SM, Lan E, Chang AH, Holcombe M, and Morris SB
- Subjects
- Adolescent, Adult, Aged, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Rifampin administration & dosage, United States epidemiology, Antitubercular Agents administration & dosage, Ill-Housed Persons, Isoniazid administration & dosage, Latent Tuberculosis drug therapy, Latent Tuberculosis epidemiology, Mycobacterium tuberculosis, Rifampin analogs & derivatives
- Abstract
Objectives: To investigate treatment outcomes and associated characteristics of persons experiencing homelessness who received 12-weekly doses of directly observed isoniazid and rifapentine (3HP/DOT) treatment for latent TB infection (LTBI)., Methods: Among homeless persons treated with 3HP/DOT during July 2011 -June 2015 in 11 U.S. TB programs, we conducted descriptive analyses of observational data, and identified associations between sociodemographic factors and treatment outcomes. Qualitative interviews were conducted to understand programmatic experiences., Results: Of 393 persons experiencing homelessness (median age: 50 years; range: 13-74 years), 301 (76.6%) completed treatment, 55 (14.0%) were lost to follow-up, 18 (4.6%) stopped because of an adverse event (AE), and 19 (4.8%) stopped after relocations or refusing treatment. Eighty-one (20.6%) had at least one AE. Persons aged ≥65 were more likely to discontinue treatment than persons aged 31-44 years. Programs reported difficulty in following up with persons experiencing homelessness because of relocations, mistrust, and alcohol or drug use., Conclusions: This study demonstrates the feasibility of administering the 3HP/DOT LTBI regimen to persons experiencing homelessness, a high-risk population., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
29. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
- Author
-
Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, Wang SH, Stewart B, Griffin P, Hunt G, Shah N, Marco A, Patil N, Mukasa L, Moro RN, Jereb J, Mase S, Chorba T, Bamrah-Morris S, and Ho CS
- Subjects
- Adolescent, Adult, Aged, Antibiotics, Antitubercular adverse effects, Antitubercular Agents adverse effects, Child, Child, Preschool, Drug Administration Schedule, Drug Therapy, Combination adverse effects, Drug Therapy, Combination methods, Drug-Related Side Effects and Adverse Reactions etiology, Female, Ill-Housed Persons, Humans, Isoniazid adverse effects, Male, Middle Aged, Rifampin adverse effects, Rifampin therapeutic use, Students, United States, Young Adult, Antibiotics, Antitubercular therapeutic use, Antitubercular Agents therapeutic use, Isoniazid therapeutic use, Latent Tuberculosis drug therapy, Mycobacterium tuberculosis drug effects, Rifampin analogs & derivatives
- Abstract
Background: Randomized controlled trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9 months of isoniazid, with a greater completion rate (82% vs 69%); however, 3HP has not been assessed in routine healthcare settings., Methods: Observational cohort of LTBI patients receiving 3HP through 16 US programs was used to assess treatment completion, adverse drug reactions, and factors associated with treatment discontinuation., Results: Of 3288 patients eligible to complete 3HP, 2867 (87.2%) completed treatment. Children aged 2-17 years had the highest completion rate (94.5% [155/164]). Patients reporting homelessness had a completion rate of 81.2% (147/181). In univariable analyses, discontinuation was lowest among children (relative risk [RR], 0.44 [95% confidence interval {CI}, .23-.85]; P = .014), and highest in persons aged ≥65 years (RR, 1.72 [95% CI, 1.25-2.35]; P < .001). In multivariable analyses, discontinuation was lowest among contacts of patients with tuberculosis (TB) disease (adjusted RR [ARR], 0.68 [95% CI, .52-.89]; P = .005) and students (ARR, 0.45 [95% CI, .21-.98]; P = .044), and highest with incarceration (ARR, 1.43 [95% CI, 1.08-1.89]; P = .013) and homelessness (ARR, 1.72 [95% CI, 1.25-2.39]; P = .001). Adverse drug reactions were reported by 1174 (35.7%) patients, of whom 891 (76.0%) completed treatment., Conclusions: Completion of 3HP in routine healthcare settings was greater overall than rates reported from clinical trials, and greater than historically observed using other regimens among reportedly nonadherent populations. Widespread use of 3HP for LTBI treatment could accelerate elimination of TB disease in the United States.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.